Table 4.
Multivariate analysis with SUVmax, MTV3.5, and TLG3.5 for DSS.
| DSS model with SUVmax | DSS model with MTV3.5 | DSS model with TLG3.5 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| P | Hazard ratio | 95% CI | P | Hazard ratio | 95% CI | P | Hazard ratio | 95% CI | |
| Sex | 0.045* | 1.822 | 1.013–3.277 | 0.031* | 1.923 | 1.062–3.481 | 0.066 | 1.723 | 0.965–3.079 |
| Age ≥66 | 0.050 | 1.928 | 1.000–3.715 | 0.066 | 1.845 | 0.066–0.961 | 0.075 | 1.813 | 0.942–3.492 |
| Resectability: BR | 0.011* | 2.199 | 1.198–4.38 | 0.039* | 1.844 | 1.033–3.292 | 0.031* | 1.895 | 1.061–3.384 |
| CA19-9 ≥276.5 | 0.140 | 1.541 | 0.867–2.739 | 0.082 | 1.665 | 0.938–2.956 | 0.139 | 1.542 | 0.868–2.737 |
| SUVmax ≥4.87 | 0.016* | 2.018 | 1.142–3.565 | ||||||
| MTV3.5 ≥2.46 | 0.011* | 2.076 | 1.187–3.632 | ||||||
| TLG3.5 ≥9.99 | 0.089 | 1.601 | 0.930–2.771 | ||||||
BR, borderline resectable; CA19-9, cancer antigen 19-9; CI, confidence interval; DSS, disease-specific survival; MTV, mean tumor volume; RFS, recurrence-free survival; SD, standard deviation; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis.
*P < 0.05.